论文信息 - The One Health Consortium: Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Combination With a Checkpoint Inhibitor in Canine Patients With Sporadic High Grade Gliomas - 字舞流文

The One Health Consortium: Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Combination With a Checkpoint Inhibitor in Canine Patients With Sporadic High Grade Gliomas

M. R. Chambers | J. Markert | D. Crossman | G. Gillespie | R. T. Bentley | S. Platt | N. Omar | D. Self | J. Foote | A. M. Waters | J. Koehler | A. Shores | D. Sorjonen | A. Waters | A. Yanke | G. Gillespie | Simon R. Platt | A. B. Yanke